CRISPR Therapeutics reports one-year CTX310 lipid-lowering data

August 28, 2026 10:31 AM

CRISPR Therapeutics (Nasdaq: CRSP) presented one-year follow-up data from its Phase 1a clinical trial of CTX310, an investigational in vivo ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found